Hims & Hers Forges Strategic Alliance with Novo Nordisk, Pivots to Branded Weight-Loss Drugs

In a significant strategic shift, telehealth provider Hims & Hers has officially partnered with pharmaceutical giant Novo Nordisk, marking a resolution to a recent legal dispute. The company has commenced offering FDA-approved GLP-1 medications, including Wegovy, while halting the aggressive promotion of its own compounded alternatives. This move aims to secure future growth, though Wall Street’s reaction has been tempered by the company’s near-term revenue guidance, which fell short of expectations.

A Partnership Born from Dispute

The path to this alliance was contentious. Earlier this year, Hims & Hers faced substantial pressure after launching its own compounded version of a weight-loss medication similar to Wegovy. Novo Nordisk promptly filed a lawsuit. The situation was further complicated by warnings from the U.S. Food and Drug Administration (FDA) and the threat of an investigation by the Department of Justice.

A deal struck in early March resolved the conflict. Novo Nordisk agreed to drop its lawsuit. In return, Hims & Hers committed to offering the original, branded pharmaceuticals at market-standard prices and to cease advertising its imitation products. Those compounded alternatives will now only remain available for a small subset of patients with specific clinical needs.

Official Launch and Service Model

The partnership moves into its commercial phase immediately. Eligible patients, following a clinician’s review, can now access various dosage strengths of the weight-loss pill Wegovy and the injectable Ozempic. Concurrently, Hims & Hers is introducing a dedicated subscription plan for weight management. Priced at $149 per month—with an introductory offer of $39 for the first month—the plan includes ongoing clinical care, nutritional counseling, and regular check-ins. The cost of the medications themselves is separate.

Should investors sell immediately? Or is it worth buying Hims & Hers?

Market Reaction and Analyst Sentiment

Despite reporting a strong fiscal 2025, where revenue surged 59% to $2.35 billion, the market response to this new strategy has been cautious. The primary concern stems from management’s forecast for the first quarter of 2026. The company anticipates revenue between $600 million and $625 million, notably below the analyst consensus estimate of approximately $653 million.

Following the partnership announcement, research firms have maintained a generally guarded stance:

• Leerink Partners: Increased its price target to $25 but maintained a “Market Perform” rating.
• Deutsche Bank: Raised its price target to $28, keeping a “Hold” rating due to near-term execution risks.
• Wall Street Consensus: The average price target stands at $31.29, accompanied by a prevailing “Hold” recommendation (as of March 16).

The first concrete evidence of the partnership’s commercial impact will arrive on May 11, 2026, when Hims & Hers reports its Q1 2026 results. This release will indicate whether the Novo Nordisk alliance is generating the anticipated momentum and beginning to close the gap with analyst projections. In the interim, the company’s focus is on educating its existing customer base about the new FDA-approved options and transitioning them to the branded medications.